Format

Send to

Choose Destination
Drugs. 2019 Apr;79(6):675-679. doi: 10.1007/s40265-019-01105-0.

Relugolix: First Global Approval.

Author information

1
Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand. dru@adis.com.

Abstract

The orally active nonpeptide gonadotropin-releasing hormone (GnRH)-receptor antagonist relugolix (Relumina) is being developed by Takeda and ASKA Pharmaceutical as a treatment for various sex hormone related disorders. Relugolix was recently approved for marketing in Japan as a treatment for symptoms associated with uterine fibroids, and studies evaluating the efficacy of the drug as treatment for endometriosis-associated pain and prostate cancer are currently underway. This article summarizes the milestones in the development of relugolix leading to this first approval for the treatment of symptoms associated with uterine fibroids.

PMID:
30937733
DOI:
10.1007/s40265-019-01105-0

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center